Quidel Corp was incorporated in the State of Delaware. It commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets diagnostic testing solutions for applications mainly in infectious diseases and reproductive and women's health. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. The Company markets its products in the U.S. through a network of national and regional distributors, and a direct sales force. Its diagnostic testing solutions are designed to provide specialized results that serve a broad range of customers, by addressing varying requirements of ease of use, reduced cost, increased test accuracy and reduced time to result. Internationally, the Company sells and markets mainly in Japan, Europe, and the Middle East through exclusive distributor arrangements. During 2012, the Company continued to invest in several key areas: support for clinical research and expanding its communications through promotional campaigns, peer-reviewed technical publications, professional shows and exhibits, symposia, medical education and support of health economics and outcomes research. In 2012, it had manufacturing operations in San Diego and Santa Clara, California and Athens, Ohio Customers for IVD products are mainly centralized laboratories and physician offices and other decentralized non-institutional settings. Its objective is to build a broader-based diagnostic company, with products in market segments that are growing to realize increased shareholder value. The Company competes with several large pharmaceutical and diversified healthcare companies. The testing, manufacture and commercialization of its products are subjected to regulation by numerous governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies.